UPDATE: BMO Capital Starts Bristol-Myers Squibb Co. (BMY) at Outperform

November 18, 2021 4:05 PM EST
Get Alerts BMY Hot Sheet
Price: $70.53 --0%

Rating Summary:
    12 Buy, 15 Hold, 4 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 6 | Down: 8 | New: 23
Join SI Premium – FREE
(Updated - November 18, 2021 4:06 PM EST)

BMO Capital analyst Evan David Seigerman initiates coverage on Bristol-Myers Squibb Co. (NYSE: BMY) with a Outperform rating and a price target of $72.00.

The analyst comments "We initiate coverage of Bristol-Myers Squibb with an Outperform rating and a $72 target price, based on: 1) Our view of strong fundamentals that are not fully reflected in current valuation, anchored by I/O and hematology businesses; 2) Margin expansion potential driven by the CV and immunology businesses; 3) Muted valuation relative to peers; and 4) Priced-in Revlimid erosion and path forward."

For an analyst ratings summary and ratings history on Bristol-Myers Squibb Co. click here. For more ratings news on Bristol-Myers Squibb Co. click here.

Shares of Bristol-Myers Squibb Co. closed at $59.44 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, Hot Comments, Hot New Coverage, New Coverage

Related Entities

BMO Capital